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Abstract
Head and neck cancer (HNC) is one of the most prevalent human malignancies, af‐
fecting different anatomic sites of the upper aerodigestive tract (UADT) such as the
oral cavity, larynx, and naso-, oro-, and hypopharynx. HNC develops through the ac‐
cumulation of multiple genetic and epigenetic alterations in a multistep process. In
this issue, the aim is to describe epigenetic mechanisms behind HNC. The main mech‐
anisms evaluated are DNA methylation, posttranslational histone modification, and
noncoding RNAs.
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1. Introduction
Genetic information flow (transcription, translation, and subsequent protein modification) in
a normal cell represents the machine of cell gene expression.[1] Each cell has the same
information, but its expression change between different types of cells. The control of gene
expression is therefore at the heart of differentiation and development.[1]
In addition to inheriting genetic information, cells inherit chemical modifications that are not
encoded in the nucleotide sequence of DNA, and this modification impacts the program of
gene expression. This type of modification has been termed epigenetic information.[1]
Epigenetic refers specifically to the study of mitotically and meiotically heritable changes in
the control of gene expression that occur without changes in the nucleotide sequence of genome
and chromatin.[2]
In both genetic and epigenetic heritage, mitosis distributes genetic information or the chemical
modification through the ontogeny. Meiosis distributes genetic information or chemical
modification through the formation of gametes. This means that sperm and egg carry genetic
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and epigenetic information. When the embryo is formed, this information is distributed
through the all the cells by mitosis (Figure 1). When it comes to population level, natural
selection determines which genetically and epigenetically inherited information is present.
Figure 1. Genetic and epigenetic information in gametes and a new embryo.
Gene regulation and genome function are intimately related to the physical organization of
genomic DNA and, in particular, to the way it is packaged into chromatin.[3] There are many
chemical modifications affecting DNA, RNA, and proteins that create different epigenetic
process.[4] These modifications are related to DNA methylation, histone modifications,
chromatin remodeling factors (associated with nucleosome positioning), and noncoding
RNAs.[4] The changes will influence the chromatin states and impact gene expression patterns
(Figure 2).[5] Epigenetic alterations are associated with chromosomal instability and changes
in transcriptional control, which influence the overall gene expression differences seen in many
human malignancies.[5]
The carcinogenesis of head and neck cancer (HNC) is a human malignancy influenced by
genetic factors, age, geography, and lifestyles, among which include smoking, oral hygiene,
and human papillomavirus.[6, 7] In general, different types of carcinogens attack the oral
mucosa through the accumulation of multiple genetic and epigenetic alterations in a multistep
process.[8] The clinical appearance of HNC preoncogenic lesion of the mucosal surfaces
include leukoplakia, erythroplakia, or speckled leukoplakia reflecting the presence of white,
red, or mixed white/red lesion, respectively.[9]
HNC is one of the most prevalent human malignancies, affecting different anatomic sites of
the upper aerodigestive tract (UADT) such as the oral cavity, larynx, and naso-, oro-, and
hypopharynx.[10] The most common histologic type among the head and neck tumors are the
squamous cell carcinomas (head and neck squamous cell carcinomas [HNSCCs]).[7]
New Aspects in Molecular and Cellular Mechanisms of Human Carcinogenesis68
It was reported that 42,440 new cases of HNSCCs were diagnosed in the United States in 2014,
and 8,390 deaths were due to this disease.[11] The mortality rate (from 2003 to 2007) was of 2.5
per 100,000 persons per year. U.S. incidence and mortality rates are about 2.5 and 2.8 in men
and women, respectively.[12]
Generally, the highest HNSCC rates are found in Melanesia, South-Central Asia, and Central
and Eastern Europe and the lowest in Africa, Central America, and Eastern Asia for both males
and females.[13]
The incidence rates for HNSCC related to HPV infections, such as oropharynx, tonsil, and
tongue base, are increasing in young adults in the United States and in some countries in
Europe, which is hypothesized to be in part due to changes in oral sexual behavior.[14]
In this issue, the aim is to describe epigenetic mechanisms behind HNSCC. The main mecha‐




DNA methylation is a chemical marking system for annotating genetic information by causing
gene repression through its ability to affect factor binding and chromatin structure.[14] This
system has gene expression patterns that are regulated in a spatial and time-dependent
manner.[5] Heritable information is carried by chemical modifications of both DNA and
chromatin-associated proteins and modulates chromatin structure and DNA accessibility.[5]
Figure 2. Genetic and epigenetic information.
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DNA methylation refers to the methylation of DNA cytosine residues at the carbon 5 position.
[15, 16] DNA methyltransferases (DNMTs) catalyze the transfer of a methyl group to position
5 of a cytosine, generating 5-methylcytosine (5mC).[17] This chemical modification affects gene
expression when CpG-rich areas are present inside promoter regions (figure 3).[16, 18] This is
accomplished by the activities of one or more DNA methyltransferases (DNMTs), which use
S-adenosylmethionine (AdoMet) as a cofactor.[19]
Figure 3. DNA methylation.
About 60% of human gene promoters are associated with CpG islands and are usually
unmethylated in normal cells, although some of them (~6%) become methylated in a tissue-
specific manner during early development or in differentiated tissues.[20]
Recent findings also suggest that extensive DNA methylation changes caused by differentia‐
tion take place at CpG island “shores,” regions of comparatively low CpG density close to CpG
islands.[2]
A relationship between DNA methylation and cancer has been found, given that DNA
methyltransferases can be genetically altered in malignancies, that is, occur with DNMT3A20
and DNMT3B.[21] Aberrant DNA methylation is an epigenetic mechanism that contributes to
the development of a wide variety of human cancers, either in the form of promoter-specific
hypermethylation or genome-wide hypomethylation.[22] Hypermethylation in gene promot‐
er regions is usually associated with expression suppression[23] and is the most common
alterations in human cancers, leading to the abnormal expression of a broad spectrum of genes.
[22] On the other hand, hypomethylation occurs in a large percentage in repetitive DNA
elements.[24]
2.2. Posttranslational covalent histone modifications
Chromatin is the state in which DNA is packaged within the cell.[25] The chromatin architec‐
ture can be remodeled by a network of protein mediators called histones that play an important
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role in gene regulation by compacting DNA.[26] The nucleosome is the fundamental unit of
chromatin, and it is composed of an octamer of histones (H2A, H2B, H3, and H4) around which
147 base pairs of DNA are wrapped.[25] Dynamic variations in the organization of chromatin
structure are mediated by histone acetylation and deacetylation (figure 4).[25]
Figure 4. Posttranslational covalent histone modifications.
Acetylation neutralizes the positive charge of lysine residues, weakening charge-dependent
interactions between histone and nucleosomal DNA, linker DNA, or adjacent histones, thus
increasing the accessibility of DNA to the transcription machinery. Histone lysine acetylation
also functions in other cellular processes that require DNA access.[27]
The posttranslational modification of histones by methylation is an important and widespread
type of chromatin modification that is known to influence biological processes in the context
of development and cellular responses.[28] Other modifications can be performed through
lysine ubiquitination, serine phosphorylation, sumoylation, and methylation of lysines and
arginines.[29]
Sumoylation is a process in which proteins are functionally or structurally similar to ubiquitin
and are termed ubiquitin-like proteins (UBLs). UBLs include SUMO, NEDD8, ISG15, and
FAT10.[30]
Histone acetyltransferases (HAT) catalyze the transfer of an acetyl group from acetyl-CoA to
ε-amino group of a histone lysine residue.[31] The action of histone deacetylases (HDAC) is
different because the effect is on the lysine residues. The first process involves chromatin
decondensation, and the second process involves chromatin compaction. Either one or the
other affects the gene transcription due to conformation changes in the chromatin.[31]
2.3. Noncoding RNAs
The noncoding RNAs are another level of epigenetic control for their capacity to establish other
epigenetic marks and control gene expression.[4] Noncoding RNA (ncRNA) is a type of RNA
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that does not code for protein but has enzymatic, structural, or regulatory function.[32]
ncRNAs can be classed as either small or long ncRNA, based on their transcript length.[33, 34]
2.4. MicroRNAs
MicroRNAs (miRNAs) are a set of non-protein-coding RNAs that bind to partially comple‐
mentary sites in the 3’-untranslated regions of their messenger RNA targets.[35] MicroRNAs
are the 21–23 nucleotide single-stranded RNA molecules found in eukaryotic cells.[36] The
miRNAs interfere with messenger RNA translation or cause messenger RNA degradation,
thereby repressing gene expression posttranscriptionally (Figure 5).[37] This is possible
through imperfect base pairing with the 3’-untranslated region (3’-UTR) of target mRNAs of
protein-coding genes, leading to the cleavage of homologous mRNA or translational inhibi‐
tion.[38]
Figure 5. RNA degradation by miRNA.
miRNAs are transcribed for the most part by RNA polymerase II as long primary transcripts
characterized by hairpin structures (pri-miRNA) and are processed in the nucleus by RNase
III Drosha into 70–100 nucleotide long precursor miRNAs (pre-miRNAs).[39]
MicroRNAs are partial complementarity between their target transcripts. A single microRNA
is capable of simultaneously regulating up to hundreds of genes, giving rise to an enormous
modulatory potential.[40]
MicroRNAs are involved in a variety of cellular processes, including the regulation of cellular
differentiation, proliferation, and apoptosis, and an aberrant expression of miRNA is known
to induce various human malignancies.[41] New evidence suggests that miRNAs can act as
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oncogenes or tumor suppressors, exerting a key function in tumorigenesis.[42] Recently, a new
function mediating tumor metastasis in breast cancer has been assigned to miRNAs, by which
this malignant step is promoted or suppressed.[42]
2.5. Long noncoding RNAs
Long noncoding RNAs (lncRNAs) are generated by the same transcriptional machinery as are
other mRNAs. These lncRNAs have a 5′ terminal methylguanosine cap and are often spliced
and polyadenylated.[45] lncRNAs have length greater than 200 nucleotides without protein-
coding potential but with a wide range of structural and functional roles.[34] Some of this
process can include the chromatin remodeling and transcriptional control assemblies.[31] They
are generally transcriptionally activated or repressed by associated transcription factors and
function as molecular mediators of gene expression.[43] When the lncRNAs act as molecular
scaffolds, they can guide the chromatin-modifying complexes to bind into specific genomic
loci. This way, they impart a repressive or activating effect on gene expression (Figure 6).[43]
Figure 6. Long noncoding RNA.
According to their association with mRNA, the LncRNAs can be divided in different catego‐
ries[44]: this can overlap with coding regions of a transcript on the same strand and with coding
regions of a transcript on the opposite strand. This can be intronic lncRNAs from other
transcript and can be intergenic lncRNAs between two genes on the same strand.[45]
The functions of the RNA in regulation of gene expression can be summarizing at transcrip‐
tional levels, RNA processing, and translation. Furthermore, they can protect genomes from
foreign nucleic acids. At chromatin level, they can modulate the genome rearrangement.
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Finally, the ncRNAs can operate as RNA–protein complexes, including ribosomes, snRNPs,
snoRNPs, telomerase, microRNAs, and long ncRNAs.[46]
Long noncoding RNAs have also been shown to be necessary for targeting histone-modifying
activities. Histone methylation is the end result of the transcription of long noncoding RNAs
and the subsequent nucleation and targeting of histone modifying completes.[27]
The aberrant expression of lncRNAs has been associated with human cancers, suggesting a
critical role in tumorigenesis.[47, 48] It has been demonstrated that a novel lncRNA, HOTAIR,
was up-regulated and promoted cancer metastasis and predicted poor prognosis in ESCC.[34]
Additionally, the association of dysregulated lncRNAs with specific developmental stages and
clinical outcomes indicates their potential as strong diagnostic and prognostic predictors as
well as therapeutic targets.[49]
3. Epigenetic changes in head and neck cancer
3.1. DNA methylation in head and neck cancer
The DNA methylation events in HNSCC include genes involved in cell cycle regulation,
signal transduction, secreted protein, transmembrane protein, transcription factors, prosta‐
glandin metabolism, metal ion homeostasis, oxidative stress, and oncoviruses.[50] Addition‐
ally, HNSCCs have genes involved in DNA damage repair, apoptosis, Wnt signaling, signal
transduction, tissue invasion/metastasis, tumor suppression, and others (Figure 7, Table 1).
[13, 51]
Figure 7. Genes and DNA methylation in HNSCC. Modified from Magić et al.,[13] Polanska et al.,[50] and Kaabi et al.
[51]
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Major classes Member Function
Cell cycle regulation p16INK4A A tumor suppressor gene regulating senescence and cell cycle
progression
p15 Cyclin-dependent kinase inhibitor
TP53 A tumor suppressor gene regulating cell cycle progression and cell
survival
PTEN A tumor suppressor gene regulating signaling pathways controlling cell
proliferation and apoptosis
Rb A proto-oncogene regulating cell cycle progression
Cyclin D1 Controls cell cycle and self-renewal of tissue stem cells
Bmi-1 Transmembrane TK that acts as a central transducer of multiple signaling
pathways
CHFR Early G2/M checkpoint
Signal transduction EGFR A transmembrane TK that acts as a central transducer of multiple
signaling pathways
VEGF A transmembrane TK that promotes proliferation, migration, and
survival of endothelial cells during tumor growth
PIK3CA A gene encoding the p110a subunit of phosphoinositide 3-kinase (PI3K) α
Secreted protein FGF-BP Fibroblast growth factors binding protein






ORAOV1 A regulator of cell growth and tumor angiogenesis
NFκB Proinflammatory transcription factor
Cox-2 Catalyzes prostaglandin synthesis from arachidonic acid
Metal ion homeostasis,
oxidative stress
MT Low molecular weight proteins involved in heavy metal detoxification,
essential metal ion homeostasis, and cell protection against free radicals
Oncoviruses EBV A causative agent for most nasopharyngeal carcinomas, plasma EBV
DNA load is an independent prognostic factor
HPV A causative agent for most oropharyngeal cancers
DNA damage repair MGMT DNA repair for alkylated guanine
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Major classes Member Function
Apoptosis DAPK p53-dependent apoptosis
RASSF1A RAS pathway regulation and tumor suppression
RARβ Regulatory protein and apoptosis
p14 Proapoptosis
Wnt signaling APC Wnt signaling and adhesion
RUNX3 Wnt signaling inhibitor, TGF-β-induced tumor sup pression
WIF1 Secreted Wnt antagonist
E-cad Cell adhesion, forming adherens junctions
DCC Cell–cell adhesion
Signal transduction SFRP1 Antagonists of the Wnt pathway
EDNRB Endothelin receptor type B
RUNX3 Wnt pathway antagonist
Tumor suppression HIN1 Inhibitor Ras pathway
DAPK1 Proapoptosis
DCC Proapoptosis
RASSF1A/RASSF2 Negative RAS effector, proapoptotic, microtubule stabilization
Others KIF1A Cell division and microtubule-dependent intracellular organelle
transport
Table 1. Genes and DNA methylation in HNSCC. Modified from Magić et al.,[13] Polanska et al.,[50] and Kaabi et al.
[51]
The primary risk factors for the development of HNSCC include tobacco use, alcohol con‐
sumption, human papillomavirus (HPV) infections (mainly for oropharyngeal cancers), and
Epstein–Barr virus (EBV) infections (for nasopharyngeal cancer).[52]
In promoter methylation, the p16 and p15 genes are commonly observed in human epithelial
malignancies, including HNSCC. Histologically normal surgical margin epithelium of HNSCC
patients with chronic smoking and drinking habits has a significantly higher prevalence of p15
methylation compared with nonsmokers and nondrinkers.[53]
Between genes that have been associated with hypermethylation, the p16 and the p14 genes
undergo inactivation due to promoter hypermethylation.[13] Encoded by the CDKN2A gene,
p16 inhibits cyclin-dependent kinases 4 and 6, thus blocking the promotion of cells from the
G1 to the S phase of the cell cycle.[54] CDKN2A (p16) inactivation is common in lung cancer
and occurs via homozygous deletions, methylation of promoter region, or point mutations.[55]
CDKN2A (p16) disruption is reported as a frequent event in head and neck squamous cell
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carcinomas that confers poor prognosis.[56] Other genes as DAP-K, RASSF1A, RARß2, and
MGMT have been reported as genes under hypermethylation promotor but with functions in
DNA repair. These genes removed mutagenic (O6-guanine) adducts from DNA.[57]
DAPK and RASSF1A genes have shown methylation in HNSCC.[58] The methylation of p16
could be an initial process that might address abnormalities or deregulation of cell cycle
controls.[59]
The ataxia-telangiectasia-mutated (ATM) gene produces a protein kinase that functions as a
tumor suppressor by triggering appropriate cellular response to genome damage resulting
from ionizing radiation or chemical carcinogen exposure.[60] It is currently unknown whether
ATM is lost in HNSCCs displaying the deletion in the 11q22–23 locus.[61]
Aggressive HNSCC has been linked to expression loss of E-cadherin (ECAD) protein.[51] The
protein ECAD can be inactivated by promoter hypermethylation.[62] In patients with HNSCC
who are low smokers, the hypermethylation of CDH1 occurs more commonly, suggesting that
an additional factor may be driving this epigenetic alteration.[62]
Cyclooxygenase-2 (Cox-2) is presumed to contribute to cancer progression through its
multifaceted function, and recently its inverse relationship with E-cadherin was suggested.
Increased expression of Cox-2 has been found in a variety of human malignancies, including
HNSCC. [63]
The death-associated protein kinase (DAPk) family contains three closely related serine/
threonine kinases, namely, DAPk, ZIPk, and DRP-1, which display a high degree of homology
in their catalytic domains.[64] The methylation profile of DAPK in HNSCC (including oral
squamous cell carcinoma) is a promising biomarker for the follow-up and early detection of
head and neck cancer recurrence.[65]
The Ras association domain family protein 1A (RASSF1A) is arguably one of the most
frequently inactivated tumor suppressors in human cancer. RASSF1A modulates apoptosis
via the Hippo and Bax pathways but also modulates the cell cycle.[66] The epigenetic inacti‐
vation of RASSF1A plays an important role in the development of cancer.[67]
TP53, once activated, leads to apoptosis and growth arrest (either cell cycle arrest or senes‐
cence). It is clear that TP53 mutation is common in HNSCC.[68] The p53 transcription factor
stands out as a key tumor suppressor and a master regulator of various signaling pathways
involved in this process.[69] Tobacco smoke is the best known and studied mutagen involved
in lung carcinogenesis, and TP53 mutational patterns differ between smokers and nonsmokers,
with an excess of G to T transversions in smoking-associated cancer.[69]
The Cancer Genome Atlas has informed about smoking-related HNSCCs and its relations
with the universal loss of function of TP53 mutations and CDKN2A. This inactivation is
accompanied with frequent copy number alterations, including amplification of 3q26/28 and
11q13/22.[70]
The phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway is antagonized by phospha‐
tase and tensin homologue (PTEN). PTEN protein is a tumor suppressor frequently disrupted
Epigenetic Mechanisms in Head and Neck Cancer
http://dx.doi.org/10.5772/61135
77
in cancer, altering tumor cell growth and survival.[71] The decrease in PTEN function in
HNSCC is due to several genetic and epigenetic alterations. Recently, promoter hypermethy‐
lation has been implicated in the down-regulation of PTEN in HNSCC cell lines.[72]
HNSCCs also exhibit many chromosomal abnormalities, including amplifications of the 11q13
region containing the cyclin D1 gene and the 7p11 region encoding EGFR, which lead to proto-
oncogene activation.[73] The most critical point in regulation of the cell cycle is the G1
checkpoint. Cyclin D1, a G1 cyclin, has been implicated in the regulation of the G1 to S phase
progression in many different cell types. Cyclin D1 forms active complexes that promote the
phosphorylation of retinoblastoma protein (RB) and the activation of E2F-responsive gene.[74]
PIK3CA is a human gene that regulates various cellular functions, including proliferation and
invasion. Because it is an oncogene, its activation by either gene amplification or mutation
results in a cellular growth advantage contributing toward cancer formation and progression.
[75] Mutations in PIK3CA have cases displayed of concurrent amplification. Additionally,
some tumors (20%) contain focal amplification without evidence of mutation. The largest
mutation proportions of PIK3CA are localized to hotspots that promote activation.[70] PIK3CA
is an active mutation that is common in conjunction with infrequent copy number alteration,
and it forms part of a subgroup of oral cavity tumors with favorable clinical outcomes.[70]
Bmi1 (B-cell-specific Moloney Murine Leukemia virus insertion site 1) is a transcription
repressor for cell senescence, implicated in the self-renewal of stem cell. Bmi1 is highly
expressed in the CD44+ cell population sorted from oral SCC tumors.[76]
E3 ubiquitin-protein ligase (CHFR) is a gene involved in a checkpoint regulating entry to
mitosis.[77] Loss of CHFR leads to mitotic catastrophe and apoptosis due to mitotic spindle
alteration. Aberrant methylation of the gene has been reported in several primary tumor genes.
EGFR is a potential prognostic biomarker.[78]
Epidermal growth factor receptor (erb-B1) is a member of the erbB family of tyrosine kinase
receptor proteins.[79] Previous studies have shown that EGFR is expressed or highly expressed
in various human tumor cells.[79] The overexpression of EGFR is attributed to gene amplifi‐
cation, which is noted to be about 12 copies per cell in relation to head and neck squamous cell
carcinomas. The constitutive EGFR activation caused via autocrine stimulation and through
the coexpression of EGFR with its ligands, TGFα, has been observed and is indicative of its
poor prognosis.[72] EGFR-targeted therapy is commonly used for the treatment of advanced
HNSCC due to numerous findings that describe overexpression and/or high activity of EGFR
in the majority of HNSCC.[80]
Various factors are known to regulate angiogenesis; for example, vascular endothelial cell
growth factor (VEGF) has potent angiogenic effects. The presence of VEGF has been reported
in approximately 40% of head and neck squamous cell carcinomas (HNSCCs), and its presence
is associated with a poor prognosis.[72]
Other mechanisms included in the tumorous angiogenesis lie in the intake and utilization of
locally stored fibroblast growth factors (FGFs).[50] FGF-1 (aFGF) and FGF-2 (bFGF) are found
in most embryonic and adult normal and tumor tissues, where they are immobilized in the
extracellular matrix (ECM).[81]
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Fibroblast activation protein (FAP) is a member of the serine protease family that is selectively
expressed in the stromal fibroblasts associated with epithelial cancers and is expressed at low
or undetectable levels in the resting fibroblasts of normal adult tissues. FAP is expressed in
more than 90% of epithelial carcinomas, which makes it a promising target.[82]
Oral cancer overexpressed 1 and 2 (ORAOV1-ORAOV2) overexpression was reported in
HNSCC.[50, 83] The first is required for cell growth and tumor angiogenesis,[84] and the
second is required in the modulation of TMEM16A activity in various epithelial tissues.[85]
Multiple signaling pathways have been linked to tumor resistance, including activation of
nuclear factor kappa B (NFκB).[86] NFκB is an epigenetic modifier that plays a major role in
malignant transformation, and this pathway serves as a target for epigenetic drugs.[26] The
constitutive activation of NFκB signaling is often observed in HNSCC, suggesting a common
epigenetic mechanism in HNSCC biology. Indeed, the activation of NFκB signaling in HNSCC
induced chromatin compaction and acquisition of resistance to chemotherapy.[26]
Metallothionein (MT) is a family of cysteine-rich, low molecular weight (500–14,000 Da)
proteins. MTs have been proposed to play important roles in protecting against DNA damage,
apoptosis, and oxidative stress. MT is a tumor suppressor reported to show promoter hyper‐
methylated in various cancers.[87]
Human mismatch repair genes (hMMR) have the ability to repair both mismatched bases and
insertion loop errors during DNA replication.[88] Suboptimal DNA repair could result in
disrupting the pattern of repeat sequences, causing chromosomal aberrations in the genome
of patients suffering from instability syndromes. Significant proportions of carcinomas
develop through DNA mismatch repair genes (MMR) deficiency and exhibit frequent micro‐
satellite alteration (MA).[88]
The hypermethylated adenomatosis polyposis coli (APC) tumor suppressor gene has reduced
expression levels along with loss of heterozygosity (LOH), leading to the altered functioning
of the APC tumor suppressor proteins, which play a role for the integrity and function of the
β-catenin destruction complex.[72] The APC protein, a negative regulator of this pathway, has
been strongly implicated in the development of colon cancer but still has an undetermined
role in the formation of oral cancer.[89]
Loss of heterozygosity of the APC gene and epigenetic events lead to the decreased expression
of APC and the Wnt antagonists, the secreted frizzled-related proteins (SFRPs), Wnt inhibitory
factors (WIFs), and Dickkopf family members (DKKs), primarily by promoter hypermethyla‐
tion.[90] The persistent β-catenin signaling contributes to increased growth, metastatic
potential, and resistance to chemotherapy in HNSCC and their tumor-initiating cells.[90] The
methylation of WIF-1 correlated with shorter survival in oral cancer patients. The methylation
of WIF1 may be considered a prognostic marker in oral cancers.[91]
Wnt pathway stimulates several intracellular signal transduction cascades (canonical and
noncanonical).[92] The possible role of RUNX3 as a tumor suppressor in HNSCC has been
reported. The promoter hypermethylation of antagonist’s genes to Wnt (RUNX3) has been
identified as a common event in cancer.[93]
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Deleted in colorectal cancer (DCC) is a candidate tumor suppressor gene located at chromo‐
some 18q21.[94] DCC promoter region hypermethylation was found in 75% of primary
HNSCC. There was a significant correlation between DCC promoter region hypermethylation
and DCC expression.[94] DCC is a putative conditional tumor suppressor gene that is
epigenetically inactivated by promoter hypermethylation in a majority of HNSCC.[94, 95]
Secreted frizzled-related protein (SFRP1) is epigenetically silenced and functions as a tumor
suppressor in oral squamous cell carcinoma (OSCC). The loss of SFRP2 expression is associated
with hypermethylation of its promoter.[96]
The methylation of the KIF1A and EDNRB gene promoters is a frequent event in HNSCC.[97]
KIF1A (kinesin family member 1A) encodes a protein that is a microtubule-dependent
molecular motor involved in important intracellular functions such as organelle transport and
cell division.[98] Endothelin receptor type B (EDNRB) is a G-protein-coupled receptor that
activates a phosphatidylinositol calcium second messenger system.[97, 99]
Runt domain transcription factors (RUNXs) are homologous to products encoded by the
Drosophila segmentation genes runt and lozenge.[100] The RUNX3 gene is located on human
chromosome 1p36, a region that has long been suspected to harbor one or more suppres‐
sors of various tumors.[101] Inactivation of RUNX3, which is caused mainly by epigenetic
alteration, is closely associated with bladder tumor development, recurrence, and progres‐
sion.[100, 101]
HIN-1 (high in normal-1) is a putative cytokine with growth inhibitory activities and is down-
regulated by aberrant methylation in breast cancers.[102] Evidence suggests that HIN-1 is a
potential tumor suppressor gene in non-small cell lung cancer (NSCLC), silenced by promoter
hypermethylation and negatively regulated by AKT signaling pathway.[103] Silencing of
HIN-1 expression and methylation of its promoter occurs in multiple human cancer types,
suggesting that the elimination of HIN-1 function may contribute to several forms of epithelial
tumorigenesis.[104]
3.2. Histone modifications in head and neck cancer
Aberrant regulation of the demethylases controlling H3K9me3 and H4K20me3 levels could
contribute to the oncogenic potential. For instance, levels of H3K4me2 and me3 are signifi‐
cantly different in oral squamous cell carcinoma in comparison with cells of the healthy tissues;
the level of H3K4me2 is increased while that of H3K4me3 is decreased.[102, 105]
A similar trend was observed in tongue squamous cell carcinoma (SCC) cells where the levels
of the H3K27me3 marks at chromatin near homeobox genes were inversely correlated with
the transcript levels in nontumorigenic, immortalized human oral keratinocytes (OKF6-
TERT1R) and tumorigenic oral SCC-9 cells.[25] This investigation found that the levels of the
H3K27me3 marks at chromatin near homeobox genes were inversely correlated with the
transcript levels in nontumorigenic, immortalized human oral keratinocytes (OKF6- TERT1R)
and tumorigenic oral SCC-9 cells.[25]
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The emerging importance of the regulation of the H3K27me3 mark as a driver of squamous
differentiation suggests that SCCs may harbor defects in the epigenetic regulation of squamous
differentiation.[106] The dysregulation of squamous differentiation is fundamental to the
development of SCC and has been reported to occur early in premalignant lesions.[107]
On the other hand, serine phosphorylation plays an important role in assembling the DNA
damage response complex by identifying DNA double-strand breaks (DSB) in the chromatin.
Upon DSB, ATM induces the phosphorylation of γH2AX at serine 139, resulting in the
recruitment of BRCA1, BRCA2, Rad51, Mre11, NBS1, FANCD2, and p53 repair proteins to sites
of DNA damage.[108]
In addition, the phosphorylation of serine 536 involved in the phosphorylation of RELA has
also been reported. RELA, also known as p65, is an REL-associated protein involved in NF-κB
heterodimer formation, nuclear translocation, and activation.[109] The phosphorylation of
serine 468 is also associated with RELA.[109]
Regarding sumoylation, there are also desumoylating enzymes called SENPs, which remove
the SUMO residues from the sumoylated proteins. Two molecules involved in the SUMO
pathway, Ubc9 and SENP5, are up-regulated in SCCs. The up-regulation of SENP5 is found
in oral SCCs, and strong SENP5 expression is correlated with poor prognosis.[110]
Finally, the lysine methylation of HSP90AB1 is important for its homodimerization and its
interaction with stress-induced phosphoprotein 1 (STIP1) and cell division cycle 37 (CDC37),
which are co-chaperones of HSP90AB1 in human cancer cells, resulting in enhancement of
cancer cell growth.[111]
3.3. miRNAs in head and neck cancer
DNA copy number variations or deregulation of miRNA expression has been shown to
contribute to carcinogenesis, including carcinogenesis of HNSCC.[112] Several studies have
reported global miRNA expression changes in carcinogenesis of HNSCC, using various
samples sizes, anatomical sites, and profiling methodologies.[113]
It has been demonstrated the differential expression patterns of miRNAs in numerous types
of cancer. MiR-92a, miR-103/107, miR-21, miR143, miR145, miR-205 and miR-296, among
others, have been confirmed to be involved in the development of esophageal squamous cell
carcinoma (ESCC).[34]
It has been reported that members of the miR-17-92 cluster were deregulated in 15 patients
with OSCC (tongue and floor of the mouth) and 35 patients with HNSCC. The miR-19a and
the miR-19b were strongly up-regulated. The miR-17-3p/miR-17-5p and the miR-92b were
moderately up-regulated. Evidence has been found that the miR-17-92 cluster is up-regulated
in many cancer types.[114] Furthermore, the miR-196a and the miR-10b, not previously
associated with HNSCC, may play an oncogenic role in this disease through the deregulation
of cell proliferation.[114]
Other studies informed that miR-21, miR-31, miR-504, and miR-10b are target tumor suppres‐
sor genes. These miRNAs are involved in HNSCC.[115] Many studies have confirmed the
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tumor suppressor roles of the let-7 family (the miR-99 family, miR-107, miR-133a, miR-137,
miR-138, and miR-375). Other miRNAs such as miR-21, let-7, miR-107, miR-138, and miR-200c
are involved in regulating stemness or the epithelial–mesenchymal transition of tumor cells.
[115]
It has also been evaluated that miR-34a is significantly down-regulated in HNSCC tumors and
cell lines.[116] The ectopic expression of miR-34a in HNSCC cell lines significantly inhibited
tumor cell proliferation, colony formation, and migration. Tumor samples from HNSCC
patients showed an inverse relationship between miR-34a and survival as well as between
miR-34a and E2F3 levels.[116]
In silico analysis identified three putative microRNA-107 (miR-107) binding sites in the 3’-
untranslated region (UTR) of PKCε.[117] An inverse relationship was revealed between
miR-107 and PKCε in HNSCC cell lines. These data demonstrated that PKCε is directly
regulated by miR-107 and, moreover, suggest that miR-107 may be a potential anticancer
therapeutic for HNSCC.[117]
New computational approach strategies complementary to microRNA profiling are capable
of simultaneously predicting tumor suppressor microRNAs as well as their functional targets
from gene expression.[118] It provided a plausible mechanism that loss of the tumor suppres‐
sor function of miR-204 as a result of allelic imbalance at 9q21.1–q22.3 may significantly
increase genetic susceptibility to HNSCC oncogenesis and progression.[118] The complete
suppression of miR-204 and its host gene TRPM3 has become possible that the mRNA
expression may serve as a marker the expression status in HNSCC.[118]
3.4. lncRNAs in head and neck cancer
LncRNAs have been linked to essential growth-promoting activities, and their deregulation
contributes to tumor cell survival. A prominent example is the Hox transcript antisense
intergenic lncRNA, HOTAIR.[119] The HOTAIR gene controls gene expression, and its
expression is deregulated in a spectrum of cancers. Furthermore, HOTAIR expression
correlates with patient survival.[119, 120]
HOTAIR serves as a scaffold for at least two distinct histone modification complexes. A 5′
domain of HOTAIR binds Polycomb Repressive Complex 2 (PRC2), while a 3′ domain of
HOTAIR binds the LSD1/CoREST/REST complex. lncRNAPCAT-1, a target gene of polycomb
repressive complex 2, has been implicated in disease progression by promoting cell prolifer‐
ation.[121] The ability to link two distinct complexes enables RNA-mediated assembly of PRC2
and LSD1 and coordinates targeting of PRC2 and LSD1 to chromatin for coupled histone H3
lysine 27 methylation and lysine 4 demethylation.[122]
In prostate cancer, the up-regulation of antisense noncoding RNA in the INK4 locus (ANRIL)
is required for the expression of the tumor suppressors INK4a/p16 and INK4b/p15.[121]
Some examples of lncRNAs that has a role in chromatin remolding include XIST, which acts
by recruiting the PRC2 complex to initiate X-chromosome inactivation as well as MALAT and
NEAT1, both of which play a role in mRNA processing and nuclear organization.[123]
New Aspects in Molecular and Cellular Mechanisms of Human Carcinogenesis82
The expression of LINC00312 in nasopharyngeal carcinoma has a tumor-suppressive function.
Under physiological conditions, LINC00312 inhibits proliferation in nasopharyngeal epithe‐
lium by preventing cell cycle passage from the G1 into S phase but increases cell adhesion,
motility, and invasion by down-regulating the expression of estrogen receptor alpha (ERα).
[124]
Other genes regulated by lncRNAs that have been implicated in cancer include NDM29,
BACE1AS, and Drosophila hsr-ω gene.[125] Neuroblastoma differentiation Marker 29
(NDM29) is an RNA polymerase (pol) III-transcribed noncoding (nc) RNA whose synthesis
drives neuroblastoma (NB) cell differentiation to a nonmalignant neuron-like phenotype.[126]
BACE1 plays a pivotal role in the accumulation of β-amyloid plaques and has been shown to
regulate the expression of BACE1 by increasing BACE1 mRNA stability.[127] The heat shock
RNA omega (hsrω) gene of Drosophila melanogaster is inducible by cell stress and provides
structural base for sequestering diverse RNA-processing/regulatory proteins.[128]
4. Clinical applications in head and neck cancer
To date, four epigenetic inhibitors have been approved by the U.S. Food and Drug Adminis‐
tration (FDA) for cancer treatment.[129] The DNMT inhibitors as 5-aza-cytidine and 5-aza-2′-
deoxycytidine are widely used in in vitro in research. The cytosine analogs are converted to
deoxynucleotide triphosphates inside the cell and then incorporated into the DNA during
replication in the original C positions.[130]
Other inhibitors of HATs approved by FDA are p300, lysine methyltransferases (H3K79
methyltransferase DOT1L, or the polycomb complex member EZH2), and lysine demethylases
(LSd1). Furthermore, small molecule inhibitors targeting the histone reader, BRD4, have also
shown promise as therapeutic agent in many cancer types.[131]
The effects of an epigenetic inhibitor as lysine residues on histone tails are HDAC inhibitors
that counteract the global overexpression of HDACs in cancer and reinstate a more permissive
nucleosome structure for transcription.[132] Vorinostat (a pan-HDAC inhibitor) and romi‐
depsin (a class I HDAC inhibitor) have each shown >30% response rates against cutaneous T-
cell lymphoma (CTCL) in phase II trials.[132]
Cetuximab is an inhibitor of the epidermal growth factor receptor (EGFR) that is used in
radiation therapy. It was found to enhance HNSCC patient survival compared with radiation
therapy alone.[133] The FDA has approved cetuximab to treat HNSCC; the drug has a response
rate of about 10% when used as a single agent in recurrent/metastatic disease.[134] However,
despite approval of cetuximab, improvement in patient survival with the use of this agent has
been only modestly incremental.[133]
Advances in oncogenomics have also identified mutations in epigenetic-associated genes that
encode histones and their linkers, proteins associated with the recruitment of DNA-binding
proteins, HDAC I and II interacting proteins, corepressor proteins, and transcriptional
activators and coactivators.[135]
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The understanding of which gene mutations, DNA methylation, posttranslational histone
modification, and noncoding RNAs drive the carcinogenesis may help us understand how
tumor susceptibility guides the development of new combination therapies. However, it is
important remember that not all cancers are equally susceptible to epigenetic therapies. The
biology underpinning this observation urgently warrants our attention if epigenetic therapies
are to be more widely applicable.[136]
5. Conclusions
Understanding the complexity of the epigenome, the different dynamics, and the different
subunits is complex and intimidating. Gene mutations, DNA methylation, posttranslational
histone modification, and noncoding RNAs are actors involved in modulating its interactions
with genomic sequences, and this is fundamental for health and disease.
Only our hope and desire can continue creating new ways to interact with the epigenome, and
it will be possible to build a new world where the HNSCC and other types of cancer will be
able to have new therapies and new opportunities for a better life.
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